Peterson Wealth Services Grows Stake in Johnson & Johnson (NYSE:JNJ)

Peterson Wealth Services raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,111 shares of the company’s stock after purchasing an additional 669 shares during the period. Peterson Wealth Services’ holdings in Johnson & Johnson were worth $1,896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Stonebridge Financial Group LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $4,817,000. BostonPremier Wealth LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $659,000. Violich Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 2.6% during the 4th quarter. Violich Capital Management Inc. now owns 100,217 shares of the company’s stock worth $14,493,000 after purchasing an additional 2,539 shares during the period. Mill Creek Capital Advisors LLC grew its holdings in Johnson & Johnson by 0.5% during the 4th quarter. Mill Creek Capital Advisors LLC now owns 248,661 shares of the company’s stock valued at $35,961,000 after purchasing an additional 1,144 shares during the last quarter. Finally, First Fiduciary Investment Counsel Inc. raised its position in Johnson & Johnson by 2.9% in the 4th quarter. First Fiduciary Investment Counsel Inc. now owns 95,515 shares of the company’s stock worth $13,813,000 after purchasing an additional 2,701 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.7 %

NYSE JNJ opened at $156.20 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a 50 day moving average price of $147.73 and a 200 day moving average price of $156.01. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays upped their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Bank of America reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Guggenheim raised their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.